| http://www.w3.org/ns/prov#value | - And the 2 that are already approved, we expect that the opportunity to offset the R&D investment that we will be making in the proteasome inhibitor's investment for these proprietary therapies, which we own 100% of around the world, except Japan, gives us an opportunity to provide all of our support behind the most important growth drivers for Onyx.
|
